S tier · elite
Tamoxifen has one of the largest randomised evidence bases in oncology, with multi-decade mortality data from ATLAS, NSABP P-1 and pooled adjuvant meta-analyses.
tamoxifen
Tamoxifen is a selective estrogen receptor modulator approved for ER-positive breast cancer treatment, adjuvant therapy, DCIS and risk reduction in high-risk women, where randomised evidence for recurrence and mortality benefit is unusually strong. Its non-oncology and steroid-ancillary uses are off-label and rest on a far thinner evidence base than its licensed indications.
the explanation
Tamoxifen blocks estrogen's effect in breast tissue and is a long-established prescription breast cancer drug with decades of large trials behind it. It also carries a boxed warning for uterine cancer, stroke and blood clots, which is why it is only used under medical supervision.
regulatory status
Approved prescription medicine
FDA-approved for ER-positive metastatic and early breast cancer, adjuvant therapy, reduction of invasive breast cancer incidence after DCIS, and risk reduction in high-risk women. Carries a boxed warning for uterine malignancies, stroke and pulmonary embolism. On the WHO Model List of Essential Medicines. Any use as a steroid ancillary or for gynecomastia is off-label.
how it works · proposed mechanism
Tamoxifen competitively occupies the estrogen receptor and produces antagonist or agonist effects depending on the tissue.
Competitive ER antagonism
Tamoxifen and its metabolites bind the estrogen receptor ligand-binding domain and displace estradiol. In breast tissue this blocks estrogen-driven transcription and slows cell cycling.
CYP2D6 metabolic activation
Tamoxifen is largely a prodrug requiring CYP2D6 hydroxylation to endoxifen, the principal active species. CYP2D6 poor-metaboliser genotypes and strong CYP2D6 inhibitors reduce endoxifen exposure.
Tissue-selective partial agonism
In endometrium, bone and hepatic tissue tamoxifen behaves as a partial ER agonist rather than a pure blocker. This preserves bone mineral density but drives endometrial proliferation and altered coagulation protein synthesis.
what’s reported
evidence shape
42 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
The very large randomised dataset behind tamoxifen was generated almost entirely in breast cancer and breast cancer risk-reduction populations, where a documented mortality benefit justifies accepting a boxed-warning risk profile. None of that evidence transfers to unsupervised use as a steroid ancillary or for anabolic-steroid-associated gynecomastia, a setting that has no comparable randomised outcome trials, no supervision for uterine or thromboembolic events, and no benefit large enough to offset a drug carrying a boxed warning.
key published findings
- Human trial (NSABP P-1, n=13,388, JNCI 1998): tamoxifen reduced invasive breast cancer incidence by 49% versus placebo (two-sided P<0.00001) in women at elevated risk, alongside a risk ratio of 2.53 (95% CI 1.35-4.97) for endometrial cancer.
- Human trial (ATLAS, Lancet 2013): among 6,846 women with ER-positive disease within 12,894 randomised, continuing tamoxifen to 10 years versus stopping at 5 gave a recurrence rate ratio of 0.84 (95% CI 0.76-0.94), with roughly 25% lower recurrence and 29% lower breast cancer mortality in the second decade after diagnosis.
- Human trial (ATLAS safety, Lancet 2013): cumulative endometrial cancer risk over years 5-14 was 3.1% with continued tamoxifen versus 1.6% with stopping (mortality 0.4% vs 0.2%), and the pulmonary embolism rate ratio was 1.87 (95% CI 1.13-3.07).
- Human trial (ATAC, Lancet Oncology 2010, n=6,241): tamoxifen produced markedly more endometrial cancer than anastrozole (24 vs 6 cases) but fewer fractures during active treatment (351 vs 451; OR for anastrozole 1.33, 95% CI 1.15-1.55, P<0.0001).
- Regulatory data (US prescribing information, NSABP P-1 rates per 1,000 women-years): endometrial adenocarcinoma 2.20 vs 0.71 placebo, uterine sarcoma 0.17 vs 0.04, stroke 1.43 vs 1.00, pulmonary embolism 0.75 vs 0.25.
limitations of the evidence
- Essentially the entire randomised dataset comes from breast cancer treatment or prevention cohorts, predominantly women; male and non-oncology data are sparse and largely observational.
- Efficacy is CYP2D6-dependent, so exposure to the active metabolite endoxifen varies substantially by genotype and by concurrent CYP2D6-inhibiting medication.
- Off-label uses such as gynecomastia and ovulation induction lack the long-horizon randomised outcome data that support the oncology indications.
documented safety signals
- Boxed warning in US labelling for uterine malignancies, stroke and pulmonary embolism, with fatal cases documented for each.
- Endometrial adenocarcinoma: risk ratio 2.53 (95% CI 1.35-4.97) versus placebo in NSABP P-1; ATLAS showed 3.1% vs 1.6% cumulative risk over years 5-14 with extended therapy.
- Uterine sarcoma, a rarer but more aggressive malignancy, reported at 0.17 vs 0.04 per 1,000 women-years in P-1.
- Venous thromboembolism including deep vein thrombosis and pulmonary embolism; PE rate ratio 1.87 (95% CI 1.13-3.07) with extended therapy in ATLAS.
- Ischaemic and haemorrhagic stroke reported at increased rates versus placebo (1.43 vs 1.00 per 1,000 women-years, P-1).
- Endometrial hyperplasia, polyps and abnormal uterine bleeding requiring gynaecological surveillance.
- Ocular toxicity including cataract and, less commonly, retinopathy and optic neuritis.
- Hepatic effects including transaminase elevation, steatosis, and rare cholestasis and hepatic necrosis.
- Hot flushes, vasomotor symptoms, mood disturbance and menstrual irregularity are common.
- Hypertriglyceridaemia, occasionally severe and associated with pancreatitis.
- Thrombocytopenia, leukopenia and rare neutropenia.
- Embryo-fetal toxicity; contraindicated in pregnancy.
- Drug interactions of consequence with warfarin (increased anticoagulant effect) and with strong CYP2D6 inhibitors such as paroxetine and fluoxetine.
- In men used off-label, suppression of the normal estrogenic feedback loop alters gonadotropin and sex-steroid dynamics in ways that have not been characterised in randomised long-term outcome studies.
identity
| full name | Tamoxifen (as tamoxifen citrate) |
| category | Ancillary & Endocrine |
| modality | small molecule |
| formula | C26H29NO |
| molar mass | 371.51 g/mol |
| cas | 10540-29-1 |
| half-life | Approximately 5-7 days (reported range 4-11 days); active metabolite endoxifen approximately 50-70 hours |
laboratory handling
| storage | Tablets and oral solution stored at controlled room temperature, approximately 20-25 degrees C, protected from light and moisture in the manufacturer's container; oral solution requires refrigeration in some presentations per the specific product label. |
| solubility | Tamoxifen free base is practically insoluble in water and soluble in ethanol, methanol and DMSO; the citrate salt used in tablets is sparingly soluble in water. |
| co-studied with | Widely discussed in non-clinical online communities as an anti-estrogen adjunct to androgen use, but there are no randomised trials evaluating tamoxifen in that role for efficacy or safety; the boxed-warning risks documented in oncology populations are not removed by using it for a different reason. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
6 citedUS prescribing information · 2024 · official
ChemicalBook · 2024 · official
StatPearls, NCBI Bookshelf · 2025 · review
Journal of the National Cancer Institute · 1998 · randomized
The Lancet · 2013 · randomized
The Lancet Oncology · 2010 · randomized
others in Ancillary & Endocrine